| Income Statement | 2025-09-30 | |||
|---|---|---|---|---|
| Research and development | 15,558 | |||
| General and administrative | 11,036 | |||
| Total operating expenses | 26,594 | |||
| Loss from operations | -26,594 | |||
| Interest income (expense), net | -96 | |||
| Other income (expense), net | 1,837 | |||
| Total other income (expense), net | 1,741 | |||
| Loss before income taxes | -24,853 | |||
| Income tax benefit | -74 | |||
| Net loss | -24,779 | |||
| Accretion of redeemable convertible preferred shares | 846 | |||
| Net income (loss) available to common stockholders, basic, total | -25,625 | |||
| Earnings per share, basic | -2.91 | |||
| Earnings per share, diluted | -2.91 | |||
| Weighted average number of shares outstanding, basic | 8,526,781 | |||
| Weighted average number of shares outstanding, diluted | 8,526,781 | |||
ImageneBio, Inc. (IMA)
ImageneBio, Inc. (IMA)